Role of Focal Adhesion Kinase in Head and Neck Squamous Cell Carcinoma and Its Therapeutic Prospect

Abstract

Head and neck cancers are one of the most prevalent cancers globally. Among them, head and neck squamous cell carcinoma (HNSCC) accounts for approximately 90% of head and neck cancers, which occurs in the oral cavity, oral pharynx, hypopharynx and larynx. The 5-year survival rate of HNSCC patients is only 63%, mainly because about 80–90% of patients with advanced HNSCC tend to suffer from local recurrence or even distant metastasis. Despite the more in-depth understanding of the molecular mechanisms underlying the occurrence and progression of HNSCC in recent years, effective targeted therapies are unavailable for HNSCC, which emphasize the urgent demand for studies in this area. Focal adhesion kinase (FAK) is an intracellular non-receptor tyrosine kinase that contributes to oncogenesis and tumor progression by its significant function in cell survival, proliferation, adhesion, invasion and migration. In addition, FAK exerts an effect on the tumor microenvironment, epithelial–mesenchymal transition, radiation (chemotherapy) resistance, tumor stem cells and regulation of inflammatory factors. Moreover, the overexpression and activation of FAK are detected in multiple types of tumors, including HNSCC. FAK inhibition can induce cell cycle arrest and apoptosis, significantly decrease cell growth, invasion and migration in HNSCC cell lines. In this article, we mainly review the research progress of FAK in the occurrence, development and metastasis of HNSCC, and put forward the prospects for the therapeutic targets of HNSCC.

Introduction

Over 650,000 individuals are diagnosed with head and neck cancer annually worldwide and over 50% of patients die from this disease, making it the sixth leading cause of cancer-related deaths globally as a motley collection of malignancies.^1,2 Head and neck squamous cell carcinoma (HNSCC) accounts for approximately 90% of all head and neck cancers that arise in the oral cavity, oral pharynx, hypopharynx and larynx.³ Alcohol and tobacco consumption is associated with the tumorigenesis of over 70% HNSCC,^4,5 and the pathogenesis of HNSCC is also related to the infection of human papilloma virus (HPV).^6,7

Surgical resection remains the preferential therapy for oral carcinoma⁸ and advanced throat carcinoma.⁹ However, due to the complex anatomical structure and various vital organs, the operation on head and neck tissue is generally difficult, usually causing the failure of radical resection. Radiotherapy is one of the main therapeutic modalities for the management of HNSCC. Yet, because of the complexity of radiotherapy target volume of the region and multiple adjacent organs in danger, more-precisely targeted radiotherapy should be explored to mitigate the long-term adverse effects of radiation, such as severe pain and delayed healing and nonunion.¹⁰ Cisplatin-based chemotherapy can be simultaneously administered with definitive radiotherapy, accompany by adjuvant radiotherapy, or as induction chemotherapy. However, the toxicity of high-dose cisplatin is enormous, and the significant survival benefits of induced chemotherapy have been rarely revealed by relevant studies.^11–13 Anti-epidermal growth factor receptor (EGFR) therapy (cetuximab) can improve the cure rate and simultaneously decrease the recurrence rate and mortality of HNSCC;¹⁴ nevertheless, no other molecular targeted therapy has been reported to prolong overall survival of patients. During the past few decades, the most notable progress in HNSCC treatment is the emergence of immunotherapy. To be specific, immunotherapy targeting programmed cell death 1(PD-1) has been recently approved for treating platinum-resistant HNSCC patients with recurrence and metastasis, which might hopefully extend tumor remission in certain patients with less toxicity than conventional chemotherapy.^15,16

Therefore, the main challenge in the treatment of tumor in the complex anatomy of the head and neck regions is to achieve high cure rates while simultaneously maintaining essential structures and functions, as vital structures and functions are also affected by tumor itself and the subsequent treatment. Organ preservation should be sufficiently considered, and all therapeutic approaches should be attempted. Meanwhile, based on the latest data, the global survival rate of HNSCC has only slightly increased in recent years. The 5-year survival rate of HNSCC patients is only 63%, mainly because approximately 80–90% of patients with advanced HNSCC tend to have local recurrence or distant metastasis.¹⁷ Therefore, it is urgent exploit novel therapeutic approaches for better survival outcomes.

FAK, a non-receptor protein tyrosine kinase with 125KDA in size, was first described in 1992 as a member of the protein tyrosine kinase (PTK) family.¹⁸ PTK2, which encodes FAK, is mapped on human chromosome 8.¹⁹ FAK can be triggered by extracellular signals such as integrin-extracellular matrix (ECM) binding and some growth factors, including G protein-coupled receptor agonists,²⁰ cytokines,²¹ epidermal growth factor,²² and hepatocyte growth factor.²³ Therefore, FAK is a multi-functional regulator of cell signal between tumor cells and tumor microenvironment.

FAK consists of an N-terminal FERM domain, a central kinase domain, a following proline-rich region and a C-terminal focal adhesion targeting (FAT) domain. The most notable role of FERM domain is the autophosphorylation site of Y397. Moreover, the FERM domain (368–375) includes the binding sites with the Src SH3. Finally, it consists of a highly conserved sequence that binds to the p-Met receptor,²⁴ phosphatidylinositol lipids (PLs),^25,26 and the C-terminal FAT domain via intramolecular interactions.²⁷ The FAK kinase domain includes the ATP binding site with the activation loop from residues 564–585. The proline-rich C-terminal region (686–917) contains the sites interacting with p130Cas,²⁸ and activating proteins of small GTPase ASAP and GRAF.^29,30 The FAT domain (922–1050), comprising extreme C-terminal, interacts with other adhesive proteins, such as paxillin³¹ and talin,^32,33 and thereby targeting FAK with focal adhesion complexes through its scaffolding protein function. The proline-rich sequences before the FAT domain (910–921) contains the phosphorylation sites of extracellular regulated protein kinase (ERK), S910.³⁴ Further, C-terminal FAK includes two major phosphorylation sites Y925 and Y861, which are both activated by Src kinases (Figure 1). Once activated by integrin-ECM engagement or growth factors, Y397 autophosphorylates the site into a high-affinity binding site to SH2 domain of Src. In FAK, Src interacts with pY397 through its SH2 domain and to the linker between the FERM and kinase domains via the SH3 domain. In turn, Src phosphorylates several tyrosines Y576 and Y577 in FAK activation zone, subsequently inducing the complete catalysis of FAK activity.

Figure 1.

The structure of FAK. PTK2 encodes FAK and is mapped on human chromosome 8q24.3. FAK consists of a FERM domain, a kinase domain, a proline-rich region and a FAT domain. FERM domain involves the Y397 autophosphorylation site and binding sites with the Src, Met and PLs, as well as the intramolecular interactions with FAT domain. The FAK kinase domain includes the ATP binding site with the activation loop. The proline-rich region contains the sites interacting with p130Casand activating proteins of small GTPase ASAP and GRAF. The FAT domain can interact with other adhesive proteins, such as paxillin and talin. The proline-rich sequences before the FAT domain contains ERK phosphorylation sites S910 and another two major phosphorylation sites Y925 and Y861.

Based on the well-known effects of FAK on diverse biological processes of cell survival, proliferation, adhesion, invasion and migration, overexpression and increased activity of FAK have been suggested to play a crucial role in tumor occurrence and development. Hence, FAK is a potential anti-tumor therapy target, particularly in HNSCC, known as an invasive tumor. This article aims to review the research progress of FAK in the tumorigenesis, development and metastasis of HNSCC, and to propose the prospects for the therapeutic targets of HNSCC.

Linkages Between FAK and HNSCC

In 2009, Xia J et al found that the expression of FAK in normal mucosa, dysplasia epithelium of varying degrees and oral squamous cell carcinoma (OSCC) tissues were significantly increased with the progression of multi-stage oncogenesis when inducing rat tongue cancer, which supported the role of FAK in oral carcinogenesis.³⁵ More recently, increased expression of FAK was found in 40 (49%) of 82 laryngeal dysplasia, whose expression was maintained or further enhanced as patient-matched dysplasia subsequently developed into invasive tumors, suggesting the involvement of FAK in malignant transformation of laryngeal cancers and its potential clinical utility as a biomarker for laryngeal cancer.³⁶ Moreover, by analyzing the immunohistochemical staining of nine benign, 19 premalignant, and 19 malignant oral tissues, Chiu YW et al showed that the immunoreactivity of FAK and pY397 was positively correlated with the degree of malignancy. Similarly, the high-invading cell line exhibited higher expression levels of FAK and phosphorylated-Y397 (p-Y397) compared with the low-invading one.³⁷ Besides, the overexpression of p-Y397, FAK Tyr-576 and FAK Tyr-925 has been recently observed in tumor zones and non-neoplastic adjacent epithelial tissue of HNSCC.³⁸ These results indicate that FAK and its phosphorylation form are correlated with tumor invasion and metastasis. Interestingly, there was an exception. In another study including48 mobile tongues squamous cell carcinoma (SCC) tissue samples, high FAK expression was significantly associated with high grade of tumor differentiation and prolonged disease-free survival of patients, which might suggest that FAK overexpression is not limited to aggressive phenotypes but also new events in HNSCC oncogenesis.³⁹

Despite some progress recent decades, the mechanisms underlying the activation and overexpression of FAK in HNSCC remains largely unclarified. Back in 1999, increased expression of FAK gene was detected in many cell lines derived from invasive epithelial tumors, which may contribute to the generally observed elevated protein expression.⁴⁰ In terms of HNSCC, relevant studies have shown that overexpression of FAK is related to gene amplification both in HPV-negative HNSCC cell lines and clinical tumors.⁴¹ Nevertheless, gain of FAK gene copy number are not always associated with increased expression or activity of FAK. In a study of 211 samples of head and neck tissues, FAK protein was overexpressed in compared with corresponding normal mucosa. Additionally, DNA copy number ratios for FAK were higher compared with normal mucosa. However, the high expression of FAK protein was independent of gain at the DNA level, and not all cases displaying FAK gene amplification showed protein overexpression. Similar data were also observed in several HNSCC-derived cell lines, where the mRNA levels of FAK were accurately correlated with its protein expression.⁴² These results suggest that FAK are involved in the tumorigenesis and development of HNSCC, providing new clues for FAK activation mechanisms instead of amplification genes. Hence, epigenetic mechanisms may also account for the overexpression and increased activity of FAK. Recent studies of human FAK gene promoters suggest that p53 and NF-κB are potential direct inhibitors and activators of promoters, respectively.^43,44 However, no correlation was found between p53 positivity and FAK expression in samples from surgically-treated supraglottic larynx SCC (with postoperative radiotherapy in 49 cases).⁴⁵ On the contrary, a more recent study investigating the expression of FAK and p53 in normal oral mucosa and OSCC revealed that FAK expression was negatively correlated with p53 expression, which supported that FAK activation might participate in p53 down-regulation in OSCC.⁴⁶ The different results of the above two studies may be due to the differences in tumor location and therapeutic approaches, which require further investigation.

Mechanisms of FAK in Oncogenesis

The overexpression of FAK in precancerous lesions of HNSCC suggests a potential role for FAK in HNSCC oncogenesis. As mentioned before, FAK can be activated by ECM integrins and growth factors in healthy cells, and multiple promotors and suppressor of tumor transformation can regulate the expression and activation of FAK. The overexpression and abnormal activation of FAK can promote the occurrence of HNSCC by regulating cell survival and proliferation (Figure 2).

Figure 2.

Multiple roles of FAK in tumor cells and multiple signaling pathways involved. FAK promotes cell survival and proliferation through caspase-mediated anti-apoptosis and G2/M cycle regulation, enhances invasion and migration via cytoskeletal rearrangement, cell polarity alteration, MMPs presentation, thus leading to oncogenesis and tumor progression.

The activation of FAK during cell adhesion has been found to protect cells from anoikis, a form of apoptosis induced by cell isolation from ECM, contributing to tumor growth and metastasis.⁴⁷ In 2012, a study revealed the high expression of p-FAK in patients with tongue OSCC. Importantly, FAK inhibitor TAE226 could significantly suppress the proliferation of human OSCC cells with an apparent structural change of actin fibre and a loss of cell adhesion. Additionally, TAE226 inhibited the expression of p-Y397, causing caspase-mediated apoptosis. Furthermore, TAE226 administration in mice OSCC xenografts suppressed the tumor growth in vivo.⁴⁸ These results offer strong evidence that FAK is closely related to OSCC and that FAK inhibitors may be potentially be used for effective OSCC treatment.

One of the mechanisms lies in FAK- Src complex formation and its interaction with Ras-GTPase activator protein SH3 domain-binding protein 1(G3BP1), which inhibits apoptosis by regulating Ras/MAPK, TGF-β/Smad, Src/FAK and p53 signaling pathways.⁴⁹ Another mechanism is that FAK induces the decreased expression of cyclin-dependent kinase (CDK) inhibitors p21 and p27. Simvastatin (a Src inhibitor) was revealed to inhibit cell proliferation, along with increased expression of p21, p27 and activated caspase-3. In contrast, the appearance of p-FAK was decreased, indicating the involvement of FAK in anti-apoptosis by reducing death receptor complex.⁵⁰

Several studies have shown that suppression of expression and activation of FAK in OSCC cell lines is correlated with caspase-dependent apoptosis and G2/M cell cycle arrest.^51,52 The suppression of different domains of FAK could induce apoptosis and cause G2/M cell cycle. Han et al used human oral keratinocytes to assess potential fenretinide-FAK drug-protein interactions and functional consequences on cellular growth regulation. The results showed that the drug-FAK interaction significantly suppressed cell proliferation by inducing apoptosis and G2/M cell cycle blockade.⁵¹

Recent researches have also shown that FAK contributes to cell survival by inhibiting the function of p53.^46,53–55 Specifically, Zhang Y et al found that apoptosis was increased by blocking FAK with an antisense oligonucleotide and decreased by blocking p53 in SCC cells. Intriguingly, p-FAK was reduced while p53 level was increased in single cells but not aggregates. These findings show that SCC cells may escape suspension-induced anoikis and obtain the metastatic phenotype under the assistance of adjacent cells and the ECM molecule fibronectin.⁵³

Apart from the decisive role in survival, FAK also promotes cell proliferation by stimulating cell cycle progression. Signaling pathways mainly include FAK/PI3K/AKT^56–59 and FAK/ERK axis.^60,61 A study showed that increased expression of FAK in slow-growing SCC25 cells could increase ERα phosphorylation, transcriptional activity and cell growth rate. Conversely, knockdown of FAK in rapidly growing OECM-1 cells decreased ERα phosphorylation and activity, and delayed cell growth.⁶² Upregulation of RACK1 protein has been reported to promote the proliferation of nasopharyngeal carcinoma (NPC) via the PI3K/AKT/FAK signaling pathway.⁵⁶

DecreasedAGO2 protein has been found to retard cell proliferation, arrest cell cycle and induce apoptosis by inhibiting the FAK/PI3K/AKT signaling pathway in FaDu cell line,⁵⁸ suggesting that AGO2 gene may be involved in malignant phenotype by acting as an oncogene. Antioncogene can also regulate the activation of FAK. CLCA2, a tumor suppressor gene, has been reported to be dysregulated in breast cancer. One recent study has suggested that it also inhibits proliferation in NPC by suppressing the FAK/ERK signaling.⁶¹

Mechanisms of FAK in HNSCC Development and Metastasis

Development and metastasis of tumor are a complex process, consisting of detachment, invasion, migration, extravasation, and proliferation of cancer cells at the distal part of the body. FAK can induce morphological changes in cells, which further contributes to cell movement. And the signaling pathway promotes tumor progression and metastasis by regulating cell adhesion, invasion and migration (Figure 2).

One important mechanism lies in the increased expression and activation of metalloproteinases (MMPs). For instance, decreased expression of MMP-2 was involved in the inhibited motility of SCC-9 and SCC-14 cells.⁶³ In another study, knockdown of FAK inhibited the invasion and migration of Tca-8113 by attenuating MMP-2 and MMP-9 activities.⁶⁴ Similar results are also detected in SCC-4 cells,^65,66 SAS cells,⁶⁷ SCC40 and SCC38 cell lines.⁶⁸ Patients with OSCC have been reported to elicit a predominance of MMP-9 activity by up-regulating the FAK/PI3K/AKT pathway.⁶⁹ Inhibition of MMP-2 and MMP-9 signaling may result from the down-regulation of PKC and RhoA by blocking MAPK and FAK/PI3K/AKT signaling pathways and NF-κB, IKK and uPA-mediated pathways.^66,67 Besides, overexpression of MMP-11 can also increase OSCC cell migration through the FAK/Src pathway.⁷⁰ A study concerning FAK-related nonkinase (FRNK) showed that FRNK expression could downregulate the expression of MMP-2 and MMP-9. In contrast, MMP-2 overexpression rescued FRNK-inhibited cell invasion in FRNK-expressing cells.⁶⁸ Another study found that phosphorylation of FAK and activation of paxillin and SATA1 pathways resulted in overexpression of target genes such as MMP-2 and MMP-26, which was suggestive of cell invasiveness and migration in HNSCC cells.⁷¹ Moreover, the expression and activity of MMP14 were found to be attenuated by inhibition of FAK (PF573228) or Src (dasatinib), thus mitigating cell invasion. Further mechanism research showed that Src-FAK/AKT/AP-1 signaling might play a role in MMP14-mediated remodeling of the ECM.⁷²

Metastasis remains a clinically unsolved issue, especially in NPC. A study found that the inhibition of colony formation and motility in NPC cells was correlated with decreased expression of p-FAK and increased expression of E-cadherin.⁷³ In another research, downregulation of E-cadherin along with enhanced cytoskeletal rearrangement and cell polarity was associated with the activation of FAK, thereby promoting cell migration.⁷⁴ RACK1 protein has been found to play an essential role in increasing the proliferation and invasion of NPC by regulating the PI3K/Akt/FAK signaling pathway.⁵⁷ Moreover, p-Y397 plays a critical role in FAK-regulated Rac1 activation and invasiveness of OSCC cells.³⁷

Recent research has demonstrated that spreading of endothelial cells in head and neck cancer was altered by inhibiting mTOR, which was associated with augmented p-FAK and enhanced migratory behaviour.⁷⁵ Abundant researches have revealed that FAK is involved signaling pathways that promote cancer cell adhesion, invasion and migration. EFNB2 specific siRNA transfected into SAS-L1 cells significantly reduced cell adhesion, invasion and migration via the phosphorylation of EGFR, FAK, AKT, ERK1/2, JNK1/2 and p38 pathways.⁷⁶ A cell cycle control kinase, aurora kinase A, was found to revive dormant tumor cells from G0 phase to active division via activating FAK/PI3K/AKT signaling, thereby promoting invasion and migration in laryngeal cancer.⁷⁷ Reduction of PTEN activates PI3K-AKT, FAK-p130Cas and Shc-MAPK/ERK1/2 signalings, which drives epithelial to mesenchymal transition (epithelial to mesenchymal transition) and consequently increases the invasion and migration of NPC cells.⁷⁸ Downregulation of RhoC leads to inactivation of FAK, Src and ERK1/2 signaling pathways in HNSCC, thus reducing cell motility, invasion colonies and stress fibre formation.⁷⁹ Knockdown of PODXL in the SAS OSCC cell line attenuated tumor invasion and migration by decreasing the phosphorylation of FAK and paxillin.⁸⁰ Cysteine-rich 61 (Cyr61) is a secretory and matrix-associated protein. Cyr61 has been indicated to enhance the migration of OSCC cells through integrin receptor, FAK, ERK, MEK and NF-κB signaling pathways.⁸¹ 5ʹ-Nitro-indirubinoxime has been reported to suppress the metastatic ability of human head and neck cancer cells through the inhibition of Integrin β1/FAK/AKT signaling.⁸² Inhibition of aquaporin 3 caused cell death, which was caused by directly interfering with cell adhesion through FAK-MAPK signaling.⁸³ Suppression of integrin α4 significantly reduced the CS1-regulated cell spreading, which was mediated by FAK.⁸⁴ A study of diabetic rats indicated that diabetes reduced cell adhesion by altering IRS-1/FAK pathway, thereby increasing the risk of oral cancer.⁸⁵ The activation of FAK may regulate the hepatocyte growth factor/scatter (HFG/SF)-induced migration of human OSCC cells.⁸⁶

FAK-Mediated Angiogenesis in Tumor

Anti-angiogenesis therapy is a promising and rational option in cancer treatment. FAK plays a role in promoting cell proliferation, invasion and migration, suggesting that FAK has a potential effect on germination of endothelial cell and angiogenesis in tumor, which composes an indispensable part in tumor metastasis. In the tongue SSC-9 cell line, the phosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2), as well as Src and FAK, downstream of the vascular endothelial growth factor (VEGF)/VEGFR2 pathway was inhibited by Sema3A, which further significantly decreased angiogenesis and drastically suppressed tumor growth.⁸⁷ FAK inhibitor TAE226 suppressed the growth and angiogenesis of OSCC xenografts in mice.⁴⁸ FRNK is the primary negative inhibitor of FAK, and its expression decreases FAK phosphorylation and inhibits EGF induced MMP-9 transcription and secretion, thereby decreasing invasion in follicular thyroid carcinoma cells.⁸⁸ All these studies highlight the role of FAK in promoting cell invasion by increasing angiogenesis.

FAK in Epithelial to Mesenchymal Transition (EMT)

EMT is considered as a prerequisite for tumor cells to acquire an aggressive or migratory phenotype and subsequent metastasis, during which polarized epithelial cells become moving interstitial cells. Therefore, EMT is crucial for the progression and metastasis of cancer.

In Kras/p53 mutant mouse model and human lung cancer cell lines, EMT has been found to activate FAK/Src signaling pathway and improve tumor cell responsiveness to the ECM composition.⁸⁹ As for HNSCC, CLCA2 has been demonstrated to suppress EMT in NPC through inhibiting FAK/ERK signaling,⁶¹ while DLC-1 can induce EMT arrest in NPC by targeting EGFR/AKT/NF-κB pathway.⁹⁰ Besides, in laryngeal cancer, AURKA induced EMT by activating FAK/PI3K pathway.⁹¹ Numb can inhibit EMT in tongue cancer via Notch1/PTEN/FAK signaling pathway.⁹² Furthermore, Western blot analysis revealed that knockdown of FAK inhibited EMT in tongue cancer cell line.⁶⁴ The FAK phosphorylation inhibitor PF573228 reversed EMT in V-SAS-LM8 cells.⁹³ Therefore, the activation of FAK is proved to promote EMT in several human HNSCC cells and play a role on EMT-induced tumor progression.

FAK in Tumor Microenvironment

ECM regulates cancer characteristics. Exploration of tumor microenvironment may shed novel light on the understanding of tumor development and metastasis.

In 2017, a study found that morphological changes affecting cell-matrix interaction, and actin cytoskeleton recombination were mainly caused by inhibiting FAK activation and increasing RhoA activity and MLC-2 phosphorylation, thus preventing cell migration.⁹⁴ In OSCC cells, silencing of AGRIN interferes with tumor cell proliferation, invasion, motility, and tumor formation, and reduces the phosphorylation of FAK, ERK and cyclin D1 proteins.⁹⁵ Mesenchymal stem cells (MSCs) within the tumor microenvironment play a critical role in tumorigenesis, progression and therapeutic response. IL1-β and CDH1 has been reported to dictate FAK and MAPKK-dependent crosstalk between cancer cells and MSCs.⁹⁶ In interstitial fibroblast, cancer vascular dissemination and local invasion were enhanced through YAP1-FAK/PXN signaling.⁹⁷ Carcinoma-associated fibroblasts (CAFs) have also been uncovered to exert an essential impact on the tumorigenesis and progression of OSCC. Knockdown of FAK in CAFs can inhibit OSCC metastasis.⁹⁸ Connective tissue growth factor (CTGF), a secretory protein binding to integrins, can reduce COX-2 expression through signal transduction pathways such as integrin receptors, FAK, PI3K, AKT, c-Jun and AP-1, thereby inhibiting migration of oral cancer cells.⁹⁹

Similarly, decreased expression of CTGF could promote cell proliferation, invasion, migration and cell cycle process through FAK/PI3K/AKT, EMT and MMP pathways in NPC.¹⁰⁰ HGF/SF factor stimulates mitogenesis and movement of an HNSCC cell line by rapidly increasing the phosphorylation of both FAK and ERK.¹⁰¹ Circulating endothelial cells are released from primary tumors and migrate to the distal sites together with tumor cells. Intriguingly, a study suggested that Bcl-2 overexpression in endothelial cells (EC-Bcl-2) significantly enhanced the expression of adhesion molecules and the binding of tumor cells, which was mainly mediated by E-selectin. Moreover, tumor cells bound to EC-Bcl-2 displayed a tendency of anti-apoptosis by activating the Src/FAK pathways.¹⁰²

FAK and Inflammatory Factors

Tumor-derived IL-1β, one mediator of the pro-inflammatory cytokine released to tumor culture medium, has been found to be positively regulated by FAK and MAPK signaling and negatively regulated by TGF-β signaling in several human cancer cell lines, including head and neck FaDu cell line.¹⁰³

TRAF2 plays an essential role in tumor necrosis factor (TNF) during inflammatory and immune responses, which physically interacts with the N-terminal portion of FAK and colocalizes to cell membrane protrusions. This cooperative interaction between TRAF2 and FAK has been confirmed to promote resistance to cell anoikis in human breast cancer cell line. Moreover, analysis of The Cancer Genome Atlas (TCGA) database revealed that co-amplification of TRAF2 and FAK in breast cancer tissues has predictive value for short survival, further supporting their potential role in cancer progression.¹⁰⁴

IL-6 has also been reported to promote metastasis in head and neck tumor by inducing EMT via the JAK-STAT3-SNAIL signaling pathway, and STAT3 knockdown significantly reversed IL-6-mediated cell motility by inhibiting FAK activation.¹⁰⁵ Inflammation is widely known to have a close relationship with tumor formation and development. At present, researches on the correlation between inflammatory factors and FAK are insufficient, thus, further evidence is warranted to profoundly demonstrate FAK role in inflammation.

Regulation of Cancer Stem Cells (CSCs)

The signal between CSCs and its ECM plays a critical role in the development and maintenance of CSC. Treatment with FAK inhibitor has revealed to decrease cell self-renewal capacities and expression of various putative stem cell markers such as Oct4, Sox2, and Nanog in a dose-dependent manner, indicating a significant role of FAK in the regulation of stemness in HNSCC.¹⁰⁶ Another study showed that CSC properties could also be regulated by the activation of the FAK-mediated signaling pathways in oesophageal squamous.¹⁰⁷ While mutant EGFRvIII-mediated cross-activation of tyrosine kinase receptor and c-Met could regulate the CSC maintenance and promote tumor recurrence in glioblastoma (GBM).¹⁰⁸

Combination with Other Treatments

The Role of FAK and FAK Targeting in Chemotherapy

Chemotherapy can be adopted as concurrent definitive radiochemotherapy, postoperative adjuvant radiochemotherapy or induction chemotherapy. However, due to the emergence of chemoresistance, many patients are not sensitive to chemotherapy and suffer from relapse after these treatments. Therefore, it is necessary to investigate the mechanisms of chemoresistance.

A study has shown that knockdown of KRT16 enhanced the chemosensitivity of OSCC towards 5-fluorouracil. Mechanistically, depletion of KRT16 inhibited the Src/STAT3/FAK/ERK signaling, thereby causing degradation of integrin β5 and c-Met.¹⁰⁹ LncRNA KCNQ1OT1 has been reported to regulate cisplatin resistance in tongue cancer via Ezrin/Fak/Src signaling.¹¹⁰ A small-molecule inhibitor targeting miR-21 has recently been found to inhibit CDK5 activity by targeting CDK5RAP1, CDK5 activators p39 and p-FAK, which is likely to be a promising strategy against taxol-induced tumor metastasis.¹¹¹ Another research has shown that up-regulated expression level of Bmi1 through a FAK-dependent mechanism led to enhanced chemoresistance against cisplatin in OTSCC cells, which adds new insights into the molecular mechanisms underlying OTSCC chemoresistance.¹¹² ECM factors in the tumor microenvironment can also control drug resistance. For instance, a study found that adhesion in the tumor matrix can create an environment in which cisplatin-induced proliferation through integrin β, talin and FAK pathways that regulate NF-kB nuclear activity.¹¹³

The Role of FAK and FAK Targeting in Radiation Therapy

Radiotherapy is a commonly used therapeutic strategy for HNSCC, but local failure following radiotherapy remains the leading cause of cancer-related death. So far, cetuximab, an inhibitor of EGFR is the only one targeted, radiosensitizing agent that has been approved for the treatment of HNSCC. However, less than 20% of all eligible patients could gain benefits from the addition of cetuximab to radiotherapy.¹¹⁴ Despite extensive studies, there are still a lack of reliable predictive biomarkers for cetuximab response. Therefore, it is definitively needed to identify new biological pathways related to radioresistance to provide other therapeutic targets.

A recent proteomic analysis showed that the overexpression of FAK was a biomarker for radioresistance in locally advanced HNSCC, and inhibition of FAK radiosensitized HNSCC cells with enhanced G2-M arrest and DNA damage.⁴¹ These results suggest that FAK inhibition combined with radiotherapy is worthy of further evaluation for elevating local control rates in HPV-negative HNSCC. Signal of integrin and receptor tyrosine kinases also play an essential role in the therapeutic resistance of malignant tumors. One study has demonstrated that FAK/ERK1-mediated antiradiation precursor signaling is effectively disrupted by integrin β1 and EGFR blockade, suggesting that integrin β1 and EGFR combined targeted therapy is an effective and promising way to overcome radiation resistance.¹¹⁵ Further researches have revealed targeting EGFR/integrin β1 radiosensitized three-dimensional SCC cell cultures, which may be due to attenuated repair of DNA double-strand breaks.¹¹⁶ Combined EGFR/FAK targeting shows more powerful radiation sensitization than either method alone, which may be based on non-overlapping signals downstream.¹¹⁷ Above all, further in-depth clarification is needed on whether EGFR and FAK dual targeting can be reasonably combined with chemoradiotherapy.

Integrin α3 has been reported to be involved in radioresistance in HNSCC cells along with integrin β1, determined by overexpression of the integrin signaling mediator FAK.¹¹⁸ Earlier, Eke I et al found that Integrin β/FAK/cortactin signaling induced cell rounding, leading to radiosensitization in human head and neck cancer,¹¹⁹ implicating that pharmacological targeting integrin β may provide therapeutic benefit to overcome tumor cell resistance to radiotherapy.

Besides, silencing fibronectin extra-domain A (EDA) has also been found to enhance the radiosensitivity of FAK/AKT/JNK pathways in NPC.¹²⁰ Another study has shown that targeting FAK radiosensitized human HNSCC cells by attenuating AKT1 and MEK1/2 signaling, actively supporting FAK as a relevant molecular target for radiotherapy in HNSCC.¹²¹ In 2009, Hehlgans S et al investigated several kinds of cancer cell lines, which revealed a dose-dependent reduction in clonogenic survival. Interestingly, TAE226 only greatly radiosensitized HNSCC cell cultures accompanied by dephosphorylation of FAK, AKT and ERK1/2, which demonstrated FAK inhibitor TAE226 enhanced the radiosensitivity particularly in HNSCC cells.¹²² However, future studies both in vitro and in vivo should be performed to clarify the specific extent of this approach may be clinically relevant to HNSCC radiotherapy.

Prognostic and Predictive Value of FAK Alterations

A retrospective study of 87 surgically treated patients with hypopharyngeal carcinoma from 2004 to 2012 in Japan found that positive staining of FAK was significantly associated with the number of metastatic lymph nodes. The disease-specific survival rate and the incidence of distant metastasis in FAK positive patients were markedly lower than those in the FAK negative patients, indicating that up-regulation of FAK expression was associated with tumor spreading and poor prognosis in patients with hypopharyngeal carcinoma.¹²³ Another research on laryngeal cancer has revealed that FAK expression was an independent predictor of tumor development, and combined use of FAK and CTTN exhibited superior predictive value, providing the first evidence for their potential clinical application as biomarkers for laryngeal cancer.³⁶ Similar results can be observed in OSCC.¹²⁴ As one of the most important prognostic factors of cancer, lymph node metastasis is widely studied in HNSCC. Jiang H et al found that the cervical lymph node metastasis of tongue cancer was significantly correlated to FAK expression.¹²⁵ In terms of patients with clinically negative lymph nodes, Rodrigo JP et al discovered that the combination of E-cadherin and FAK expression could improve the differential diagnosis of patients who were at considerable risk for occult metastases.¹²⁶ Further study has shown that increased expression of FAK Tyr-576 could identify tumors with more aggressive behavior and epithelial alterations before clinical or histological evaluations.³⁸

Moreover, studies show the potential application of FAK protein expression as a risk marker in tumor. For instance, an immunohistochemical study of 109 patients with precancerous laryngeal lesions supports the applicability of CTTN and FAK as auxiliary indicators of risk stratification.¹²⁷ In another research enrolling patients with HPV-negative locally advanced HNSCC, gene amplification and mRNA expression of FAK were both greatly associated with worse disease-free survival.⁴⁴ However, there are some exceptions. In a retrospective study of 224 HNSCC patients treated with primary radiation (chemotherapy) from 1996 to 2005, the expression of FAK and p-FAK was not associated with local control and distant metastasis.¹²⁸

Similarly, weak FAK expression is also related to lymph node metastasis, recurrence and wretched prognosis in cervical cancer.¹²⁹ These results suggest that FAK might promote the malignancy of primary neoplasia, yet not definitely leading to distant metastasis. The prognosis potential of FAK may also be related to its therapeutic effects.

Potential Clinical Use of FAK

There are a number of candidates under different stages of pre-clinical and clinical trials and potential efficacy responses in tumor regression and disease stabilization have been observed.

PF-562,271 (also termed VS-6062) is a bisamino pyrimidine derivative as a FAK activity inhibitor. With VS-6062, 31 patients (34%) experienced stable disease (SD) at the first restaging (end of cycle 2). Fifteen of these patients had SD for six or more cycles including two cases of HNSCC.¹²⁹ Results from the Phase II clinical trials (NCT01951690) for Defactinib (VS‐6063) in patients with KRAS mutant non-small cell lung cancer showed that the drug was generally well tolerated and suitable for long‐term dosing. It is also found that FAK inhibitors need to be combined with other agents as they have not yet shown evidence of single agent activity. Pre-clinical trials for selective FAK inhibitor VS-4718 showed that FAK inhibition enhances immune surveillance by overcoming fibrosis and the immunosuppressive tumor microenvironment in pancreatic ductal adenocarcinoma, thus enabling tumors to respond to immunotherapy.¹³⁰ Recently, the combination of the FAK inhibitor GSK2256098 and the MEK inhibitor trametinib in recurrent advanced pancreatic ductal adenocarcinoma did not provide significant clinical activity in a phase II trial with the PFS of 1.6 month and OS of 3.6 months.¹³¹ In malignant pleural mesothelioma, defactinib in maintenance after first-line chemotherapy in a phase II trial did not provide any benefit either.¹³² Several clinical trials with defactinib associated with immunotherapy (NCT02758587, NCT03727880, NCT02943317), RAK/MEK inhibitor (NCT03875820), or chemotherapy (NCT02546531) are ongoing.

Conclusions and Future Directions

This review mainly summarizes the role of FAK in cell survival, growth, adhesion, invasion, migration, EMT, and regulation of tumor microenvironment, CSCs, inflammatory factors and radiation (chemotherapy) resistance. These constitute one of the strongest rationales for FAK inhibition as a potential target in HNSCC treatment, whose effects are mediated by changing both tumor and stromal cell biology. Future studies are necessary to confirm whether FAK signaling plays a decisive role in the development and progression of HNSCC or just performs as a combination with other signaling pathways. At present, there are several Phase I studies evaluating the safety and activity of FAK inhibitors, including PF-562,271, Defactinib, VS-4718 and GSK2256098, among solid tumors. However, there is no information about FAK inhibitor in phase II studies in HNSCC patients at present. Future directions include possible combination studies with existing standard and emerging therapies (PD-1/PD-L1, MEK inhibitors and chemotherapy). Therefore, we hope to develop specific FAK inhibitors with clinical significance in HNSCC biology through the regulation of radiation (chemotherapy) resistance, anti-tumor immunity and angiogenesis. Moreover, the role of FAK alteration in predicting HNSCC prognosis is still unclear and more well-designed clinical trials and high-quality Mata analysis are needed. Further research is needed to find predictive biomarkers of response to FAK TKI alone or, probably more promising, in association with another drug. Future research into the FAK-associated pathways will elucidate new therapeutic combinations and biomarkers for patient stratification.

Disclosure

The authors report no conflicts of interest in this work.